Welcome to our dedicated page for Calumet SEC filings (Ticker: CLMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Calumet, Inc. filings document operating results, governance matters and capital-structure actions for a Nasdaq-listed specialty products and renewable fuels company. The record includes Form 8-K disclosures for quarterly and annual results, Regulation FD communications, material definitive agreements, credit-agreement amendments, direct financial obligations and senior-note transactions involving subsidiaries Calumet Specialty Products Partners, L.P. and Calumet Finance Corp.
Proxy materials describe annual meeting voting matters, board elections and related governance disclosures. The filings also identify Calumet's common stock, par value $0.01 per share, under symbol CLMT on The Nasdaq Stock Market LLC and provide formal disclosure around debt terms, covenant changes, risk-related governance and shareholder matters.
Calumet, Inc. reported fourth quarter and full-year 2025 results showing sharply improved profitability and major balance sheet actions. For 2025, sales were $4,137.1 million versus $4,189.4 million in 2024, while net loss narrowed to $33.8 million from $222.0 million. Adjusted EBITDA was $211.2 million and Adjusted EBITDA with Tax Attributes reached $293.3 million, helped by Clean Fuel Production Credits.
The Specialty Products and Solutions segment delivered 2025 Adjusted EBITDA of $291.8 million, up from $222.5 million, with higher adjusted gross profit per barrel. Performance Brands’ Adjusted EBITDA declined to $47.9 million, reflecting a divestiture and nonrecurring insurance proceeds, while Montana/Renewables posted segment Adjusted EBITDA of $(50.8) million but positive Adjusted EBITDA with Tax Attributes of $31.3 million.
Operating cash flow swung to an inflow of $108.9 million from an outflow of $46.4 million in 2024. Management highlighted about $100 million of structural cost reductions and paydown of $222 million of recourse debt. In January 2026, Calumet issued $405 million of 9.75% Senior Notes due 2031 and used proceeds, with cash and revolver borrowings, to redeem 2026 and 2027 notes, and extended its $500 million ABL facility to 2031.
Calumet, Inc. director Raymond Paul C reported awards of restricted stock units that are economically equivalent to common shares. On February 24, 2026, he acquired 854 Restricted Stock Units that are 100% vested and will be settled upon the earlier of a specified date or his termination date. He also acquired 284 Restricted Stock Units that will be settled under a Deferred Compensation Plan, with 25% vesting each July 1 beginning on July 1, 2027.
Boss John G. reported acquisition or exercise transactions in this Form 4 filing.
Calumet, Inc. director John G. Boss reported receiving two grants of restricted stock units that are each economically equivalent to one share of common stock. One grant covers 256 units that are already 100% vested and will be settled on either a specified date or his termination date. A second grant covers 85 units under a deferred compensation plan, with 25% of these units scheduled to vest on July 1 of each year beginning on July 1, 2027, and settling on the earlier of a specified date or his termination date.
Mawer Stephen P reported acquisition or exercise transactions in this Form 4 filing.
Calumet, Inc. director Stephen P. Mawer received grants of restricted stock units that are the economic equivalent of common shares. One award covers 1,175 restricted stock units that are 100% vested and will be settled upon the earlier of a date he specifies or his termination date. A separate award covers 391 restricted stock units under a deferred compensation plan, which will be settled on the earlier of a specified date or his termination, with 25% of these units vesting each July 1 beginning in 2027.
Calumet, Inc. director Amy M. Schumacher reported the grant of two sets of restricted stock units tied to the company’s common stock. She acquired 782 Restricted Stock Units that are already 100% vested and will be settled upon the earlier of a date she specifies or her termination. She also received 260 Restricted Stock Units under a deferred compensation plan, with 25% scheduled to vest on July 1 of each year beginning in 2027, and these units will be settled on the earlier of a specified date or her termination.
Calumet, Inc. director Daniel J. Sajkowski reported mixed equity transactions involving Calumet, Inc. (CLMT) on common stock and restricted stock units. He completed an open-market sale of 2,022 shares of common stock and reported exercises/conversions of 5,053 restricted stock units into common stock. After these transactions, his directly held common stock position was 87,290 shares. The filing notes that each restricted stock unit is economically equivalent to one share of common stock, is 100% vested, and may be settled in either stock or its cash value, with 40% of the vested units elected to be settled in cash.
Calumet, Inc. director Daniel J. Sajkowski reported equity award activity and a small share sale. On June 24, 2025, he exercised 3,796 Restricted Stock Units, converting them into 3,796 shares of common stock at a price of $0.00 per share.
Footnotes state each Restricted Stock Unit is economically equivalent to one common share and is 100% vested, and that he elected to receive 40% of the vested units in cash rather than stock. On the same date, he sold 1,518 common shares, leaving a direct holding of 84,237 common shares after the transactions.
Calumet, Inc. director Daniel J. Sajkowski reported a series of open-market sales of common stock under a pre-arranged Rule 10b5-1 trading plan. Between March 3 and July 1, 2025, he sold a total of 82,000 shares of common stock in five transactions at reported weighted average prices ranging from $10.66 to $15.77 per share. After the most recent sale of 2,000 shares at $15.77 per share, his direct holdings stood at 82,237 shares of Calumet, Inc. common stock.
Krutz John Robert reported acquisition or exercise transactions in this Form 4 filing.
Calumet, Inc. /DE reported that Chief Accounting Officer John Robert Krutz received a grant of 2,365 Restricted Stock Units on February 24, 2026. Each unit is the economic equivalent of one share of Calumet, Inc. common stock, and these units vest on February 24, 2029. After this award, Krutz holds 2,365 Restricted Stock Units directly.
Lunin David reported acquisition or exercise transactions in this Form 4 filing.
Calumet, Inc. executive vice president and CFO David Lunin reported receiving two grants of restricted stock units, totaling 9,786 and 7,080 units. Each unit equals one share of common stock. The 2025 performance-based units remain subject to service vesting through February 25, 2028, and the additional units vest on February 24, 2029.